Jieduquyuziyin Prescription Suppresses Inflammatory Activity of MRL/lpr Mice and Their Bone Marrow-Derived Macrophages
IRAK1-NF-κB signalling
Jieduquyuziyin prescription
MRL/lpr mice
bone marrow-derived macrophages
inflammatory activity
systemic lupus erythematosus
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
03
2020
accepted:
26
06
2020
entrez:
8
8
2020
pubmed:
8
8
2020
medline:
8
8
2020
Statut:
epublish
Résumé
Jieduquyuziyin prescription (JP) has been used to treat systemic lupus erythematosus (SLE). Although the effectiveness of JP in the treatment of SLE has been clinically proven, the underlying mechanisms have yet to be completely understood. We observed the therapeutic actions of JP in MRL/lpr mice and their bone marrow-derived macrophages (BMDMs) and the potential mechanism of their inhibition of inflammatory activity. To estimate the effect of JP on suppressing inflammatory activity, BMDMs of MRL/lpr and MRL/MP mice were treated with JP-treated serum, and MRL/lpr mice were treated by JP for 8 weeks. Among them, JP and its treated serum were subjected to quality control, and BMDMs were separated and identified. The results showed that in the JP group of BMDMs stimulated by Lipopolysaccharide (LPS) in MRL/lpr mice, the secretion of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) reduced, and the expressions of Interleukin-1 receptor-associated kinase 1 (IRAK1) and its downstream nuclear factor κB (NF-κB) pathway decreased. Meanwhile, the alleviation of renal pathological damage, the decrease of urinary protein and serum anti-dsDNA contents, the inhibition of TNF-α level, and then the suppression of the IRAK1-NF-κB inflammatory signaling in the spleen and kidney, confirmed that the therapeutic effect of JP. These results demonstrated that JP could inhibit the inflammatory activity of MRL/lpr mice and their BMDMs by suppressing the activation of IRAK1-NF-κB signaling and was supposed to be a good choice for the treatment of SLE.
Identifiants
pubmed: 32760274
doi: 10.3389/fphar.2020.01049
pmc: PMC7372094
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1049Informations de copyright
Copyright © 2020 Ji, Fan, Hou, Fu, Bao, Zhuang, Chen, Fan and Li.
Références
Mol Med Rep. 2017 Sep;16(3):3111-3116
pubmed: 28714001
Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7401-7403
pubmed: 30468487
J Immunol. 2015 Dec 15;195(12):5787-94
pubmed: 26561545
Biomed Pharmacother. 2018 May;101:777-785
pubmed: 29525672
PLoS One. 2015 Jul 24;10(7):e0133724
pubmed: 26208003
Science. 2017 May 5;356(6337):513-519
pubmed: 28473584
Lupus. 2012 Jul;21(8):848-54
pubmed: 22415926
J Immunol. 2010 Jun 1;184(11):6465-78
pubmed: 20427764
Evid Based Complement Alternat Med. 2019 Nov 3;2019:2357217
pubmed: 31781262
Immunol Rev. 2012 Mar;246(1):5-13
pubmed: 22435544
Eur Rev Med Pharmacol Sci. 2019 Aug;23(16):7024-7032
pubmed: 31486503
J Clin Immunol. 2013 Jul;33(5):925-37
pubmed: 23479181
PLoS One. 2015 Feb 17;10(2):e0118462
pubmed: 25689512
Inflammation. 2016 Apr;39(2):849-59
pubmed: 26956469
PLoS One. 2015 Jun 25;10(6):e0121256
pubmed: 26110642
Front Pharmacol. 2019 Jan 07;9:1516
pubmed: 30666206
J Exp Med. 2005 Mar 21;201(6):915-23
pubmed: 15767370
Oxid Med Cell Longev. 2018 Nov 8;2018:9364364
pubmed: 30533177
Exp Ther Med. 2019 Oct;18(4):3078-3084
pubmed: 31572547
Mol Immunol. 2017 Jul;87:94-101
pubmed: 28431280
Front Immunol. 2015 Sep 15;6:475
pubmed: 26441980
Front Pharmacol. 2019 Feb 05;10:27
pubmed: 30804780
Biochem Pharmacol. 2010 Dec 15;80(12):1981-91
pubmed: 20599782
Cell Physiol Biochem. 2015;37(4):1279-88
pubmed: 26431544
PLoS One. 2014 Feb 05;9(2):e88223
pubmed: 24505438
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6256-61
pubmed: 19329491
In Vitro Cell Dev Biol Anim. 2018 Dec;54(10):692-704
pubmed: 30367366
Front Immunol. 2016 Jan 19;6:650
pubmed: 26834734
Neuropharmacology. 2014 Apr;79:642-56
pubmed: 24467851
J Exp Med. 2011 Jun 6;208(6):1215-28
pubmed: 21606507
Nat Rev Immunol. 2006 Nov;6(11):823-35
pubmed: 17063184
Microb Pathog. 2018 Nov;124:223-229
pubmed: 30149133
Cell Mol Neurobiol. 2015 May;35(4):523-31
pubmed: 25504431
Cell Mol Immunol. 2011 Sep;8(5):388-403
pubmed: 21822296
Front Immunol. 2020 Jan 24;10:3020
pubmed: 32082297
J Autoimmun. 2015 Feb;57:42-52
pubmed: 25554644
Pharmacol Ther. 2020 Mar;207:107452
pubmed: 31836457
Clin Exp Hypertens. 2019;41(6):524-530
pubmed: 30183401
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3012-7
pubmed: 20133703
Autoimmun Rev. 2010 Nov;10(1):38-42
pubmed: 20817127
J Autoimmun. 2010 Dec;35(4):291-8
pubmed: 20810248
J Ethnopharmacol. 2018 May 10;217:220-227
pubmed: 29476961
Ann Rheum Dis. 2013 Mar;72(3):437-44
pubmed: 22904263
Biochemistry (Mosc). 2016 Mar;81(3):289-95
pubmed: 27262199
Arthritis Rheumatol. 2014 Jun;66(6):1596-607
pubmed: 24866269
J Immunol. 2016 Dec 1;197(11):4266-4273
pubmed: 27807192
Reumatologia. 2019;57(5):264-270
pubmed: 31844338
J Nat Med. 2015 Jul;69(3):349-57
pubmed: 25821132
Eur J Immunol. 2017 May;47(5):880-891
pubmed: 28295231
Lupus. 2012 Jul;21(8):830-5
pubmed: 22343096
Immunobiology. 2018 Apr - May;223(4-5):349-355
pubmed: 29096944
Immunol Invest. 2018 Jul;47(5):468-483
pubmed: 29611775
Arthritis Rheum. 2011 Nov;63(11):3493-501
pubmed: 21792837
Lancet. 2013 Aug 31;382(9894):809-18
pubmed: 23972423